FEB 23, 2017 12:00 PM PST
Recent progress in cellular medicine with an eye to precision medicine
Presented at the Precision Medicine 2017 Virtual Event
2 1 67

  • Donner Professor of Science and Professor of Chemistry, Emeritus
      Giacinto Scoles (b. 1935, married to Lim Giok Lan since 1964) is Donner professor of Science, Emeritus at Princeton University, distinguished adjoint professor in the Departments of Physics and Biology at Temple University, and distinguished scientist at Synchrotron Elettra in Trieste. He is presently senior grantee of the ERC in the faculty of Medicine at the University of Udine (Italy). His career has spanned an unusually long length of time and an equally unusually broad range of subjects. He has developed instrumentation in mass spectroscopy, gas viscosimetry, crossed molecular beam scattering, clusters formation and spectroscopy, surface monolayer, grazing incidence X-ray scattering, super-fluid helium droplets; manipulation of bio-molecules, bio-molecular interaction at the nano scale and medical nano diagnostics. He and a group of collaborators have recently patented a method to count circulating tumor cells based on the measurement of the metabolism of every cell isolated into a droplet of blood of several picoliters. When the droplet results to become acid, that indicates the presence of the cancer cells. He has received several recognitions: the Herschbach prize (2013); the gold medal of honor of the Italian Chemical Society; the Ben Franklin Medal for Physics (2006) 2 Honorary doctorates (1997 and 2000) the Debye prize of the ACS, the Plyler prize of the APS and the Lippincott Award of the OSA. He is a Fellow of the APS, OSA and of the ROYAL Society of the UK and of the Royal Science Academy of the Netherlands (KNAW). He has published about 300 papers in peer reviewed journals, and has been quoted by his colleagues approximately 19.000 times, his H-index is 73, while the i10-index is 224. He has supervised about a hundred PhD students, an unusually high percentage of which now covers positions of responsibility in Academia and research.


    Despite vast investment for decades in cancer research and development, cancer is still among the leading causes of death worldwide and its toll is expected to rise by about 70% over the next two decades. There are many aspects of cancer, including its complexity, diversity, and dynamic nature, which call for a radical change in the way we approach cancer study and management. For instance, the genetic profile of tumors affects patient tumor response while the tumor microenvironment plays a critical role in cancer development, progression, and control. Due to intra-tumoral heterogeneity, cancer cells extracted from the same tumor of a patient may be genetically heterogeneous. Tumor/host immune interactions influences disease outcome by altering the balance of suppressive versus cytotoxic responses in the vicinity of the tumor. In addition, biopsies often suffer from sample bias, and tumor sampling from some cancer types still remains difficult resulting in insufficient amount of tissue for genetic testing. Considering the high tumor heterogeneity from individual patients, it is increasingly recognized that a personalized medicine approach would help identifying the optimal treatment regimen for an individual patient, calibrated on his/her specific cancer signature, reducing toxicity from overtreatment and increasing efficacy of therapy.

    However, in order to pursue personalized approaches, novel approaches capable of improving the care of cancer patients through earlier detection, better therapy monitoring, new drug development and rational treatment planning are urgently needed.

    One of the challenges of personalized medicine is related to the so-called liquid biopsy, that is the extraction of circulating tumor cells (CTC) and cell-free or circulating tumor DNA (ctDNA) from peripheral blood, which is expected to revolutionize the way in which cancer care works nowadays, by providing easy and repeatable access to tumor biological material, and consequently to the information about disease state, prognosis and chemo-sensitivity contained in it. On the other hand, also because of the epithelial-to-mesenchymal transition, not much is known at present about how the peripheral blood samples the tumor material, adding urgency to the type of study discussed above. Another challenge of personalized medicine is represented by the assembly of suitable in vitro tumor models capable of predicting the response to specific chemotherapeutic agents for each patient. I will present to you today a new method to recognize, count, sort and analyze CTCs.

    Show Resources
    Loading Comments...